BPC-157 + TB-500 (Wolverine Stack) – 10mg / 10mg (3ml Pen)

This is the reference combination of the tissue repair category, pairing the two most studied compounds in the field. The research rationale is complementary rather than additive: the two peptides act on different stages of the repair sequence, one on vascular supply and one on the cellular movement that follows it. Both carry large preclinical literatures, and combination-specific research is comparatively limited.

The combination pairs two mechanistically distinct repair peptides. Research describes BPC-157 as acting on VEGFR2 signalling and nitric oxide pathways with associated angiogenesis, alongside effects on fibroblast migration and collagen organisation. TB-500 is described as sequestering G-actin monomers, regulating cytoskeletal reorganisation and thereby cell motility, with downstream effects on endothelial and keratinocyte migration. The proposed rationale is that vascular supply and cellular migration represent sequential requirements in tissue repair rather than overlapping ones.

Both constituents carry substantial individual preclinical literatures. Research on the specific combination is limited, and the rationale rests principally on mechanistic complementarity rather than direct combination study.

BPC-157 research

Extensive rodent work across gastrointestinal, tendon and vascular injury models.

TB-500 research

Preclinical and early clinical work on cell migration in cardiac, corneal and dermal models.

Mechanistic complementarity

The two peptides act on distinct and sequential stages of the repair process.

Combination evidence

Direct research on the paired combination is limited relative to the individual compounds.

Anti-doping context

TB-500 is listed by anti-doping authorities.